Eli Lilly and Company (LLY)
- Previous Close
755.91 - Open
743.00 - Bid 740.00 x 1200
- Ask 740.00 x 900
- Day's Range
730.34 - 745.00 - 52 Week Range
419.80 - 800.78 - Volume
4,535,212 - Avg. Volume
3,044,188 - Market Cap (intraday)
698.519B - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
108.72 - EPS (TTM)
6.76 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield 5.20 (0.71%)
- Ex-Dividend Date Feb 14, 2024
- 1y Target Est
855.36
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
www.lilly.com43,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: LLY
Performance Overview: LLY
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LLY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LLY
Valuation Measures
Market Cap
698.52B
Enterprise Value
722.14B
Trailing P/E
108.24
Forward P/E
56.50
PEG Ratio (5yr expected)
1.25
Price/Sales (ttm)
18.48
Price/Book (mrq)
54.52
Enterprise Value/Revenue
20.10
Enterprise Value/EBITDA
74.53
Financial Highlights
Profitability and Income Statement
Profit Margin
17.08%
Return on Assets (ttm)
12.60%
Return on Equity (ttm)
50.75%
Revenue (ttm)
35.93B
Net Income Avi to Common (ttm)
6.14B
Diluted EPS (ttm)
6.76
Balance Sheet and Cash Flow
Total Cash (mrq)
2.65B
Total Debt/Equity (mrq)
204.28%
Levered Free Cash Flow (ttm)
-1.23B
Research Analysis: LLY
Company Insights: LLY
LLY does not have Company Insights